So EC - Search Results

1

Impact of Detachment Methods on M2 Macrophage Phenotype and Function.

Chen S, So EC, Strome SE, Zhang X. Chen S, et al. Among authors: so ec. J Immunol Methods. 2015 Nov;426:56-61. doi: 10.1016/j.jim.2015.08.001. Epub 2015 Aug 5. J Immunol Methods. 2015. PMID: 26253940

2

A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity.

So EC, Sallin MA, Zhang X, Chan SL, Sahni L, Schulze DH, Davila E, Strome SE, Jain A. So EC, et al. J Immunol Methods. 2013 Aug 30;394(1-2):40-8. doi: 10.1016/j.jim.2013.05.001. Epub 2013 May 13. J Immunol Methods. 2013. PMID: 23680234

3

CD40 mediates downregulation of CD32B on specific memory B cell populations in rheumatoid arthritis.

Zhang X, Burch E, Cai L, So E, Hubbard F, Matteson EL, Strome SE. Zhang X, et al. J Immunol. 2013 Jun 15;190(12):6015-22. doi: 10.4049/jimmunol.1203366. Epub 2013 May 17. J Immunol. 2013. PMID: 23686494

4

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.

Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE. Jain A, et al. Among authors: so ec. Eur J Cancer. 2013 Oct;49(15):3344-52. doi: 10.1016/j.ejca.2013.06.009. Epub 2013 Jul 18. Eur J Cancer. 2013. PMID: 23871153

5

The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.

Sallin MA, Zhang X, So EC, Burch E, Cai L, Lin W, Chapoval AI, Strome SE. Sallin MA, et al. Among authors: so ec. Cancer Immunol Immunother. 2014 Sep;63(9):947-58. doi: 10.1007/s00262-014-1567-2. Epub 2014 Jun 14. Cancer Immunol Immunother. 2014. PMID: 24927849 Free PMC article.

6

Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.

Zhang X, Olsen HS, Chen S, So E, Zhou H, Burch E, Mérigeon EY, Block DS, Strome SE. Zhang X, et al. J Immunol. 2016 Feb 1;196(3):1165-76. doi: 10.4049/jimmunol.1501755. Epub 2015 Dec 22. J Immunol. 2016. PMID: 26695368

7

Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease.

Sun H, Olsen HS, Mérigeon EY, So E, Burch E, Kinsey S, Papadimitriou JC, Drachenberg CB, Bentzen SM, Block DS, Strome SE, Zhang X. Sun H, et al. J Autoimmun. 2017 Nov;84:97-108. doi: 10.1016/j.jaut.2017.08.004. Epub 2017 Aug 19. J Autoimmun. 2017. PMID: 28830653

8

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.

Zhou H, Olsen H, So E, Mérigeon E, Rybin D, Owens J, LaRosa G, Block DS, Strome SE, Zhang X. Zhou H, et al. Blood Adv. 2017 Mar 14;1(8):504-515. doi: 10.1182/bloodadvances.2016001917. eCollection 2017 Mar 14. Blood Adv. 2017. PMID: 29296968 Free PMC article.

9

A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity.

Zhang X, Owens J, Olsen HS, So E, Burch E, McCroskey MC, Li X, Weber GL, Bennett D, Rybin D, Zhou H, Hao H, Mérigeon EY, Block DS, LaRosa G, Strome SE. Zhang X, et al. JCI Insight. 2019 Jan 24;4(2):e121905. doi: 10.1172/jci.insight.121905. JCI Insight. 2019. PMID: 30674715 Free PMC article.

10

NK cell expression of Tim-3: First impressions matter.

So EC, Khaladj-Ghom A, Ji Y, Amin J, Song Y, Burch E, Zhou H, Sun H, Chen S, Bentzen S, Hertzano R, Zhang X, Strome SE. So EC, et al. Immunobiology. 2019 May;224(3):362-370. doi: 10.1016/j.imbio.2019.03.001. Epub 2019 Mar 2. Immunobiology. 2019. PMID: 30876792 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page